MONTRÉAL, May 21, 2021 /CNW Telbec/ - The Fonds de solidarité FTQ is investing $3 million in Giiant Pharma, a Montreal-based preclinical biotech firm that today announced the closing of $13.5 million in financing.
Read MoreThe COVID-19 pandemic has underlined the essential role of the biotechnology sector. Québec has a wealth of talented researchers and entrepreneurs in several specialties, including neurology, oncology, rare diseases and cardiology. And investors in the province believe that the life sciences will play a major economic role in the post-coronavirus era.
Read MoreMONTRÉAL, April 8, 2021 /CNW Telbec/ - Fonds de solidarité FTQ (the « Fonds ») is investing US$4 million in Ventus Therapeutics. Created in 2019 by Versant Ventures, Ventus is pioneering a unique approach to structure-based drug discovery to address biologically validated, but elusive, drug targets. The company is rapidly advancing a pipeline of new medicines to treat autoimmune and inflammatory diseases, neurological disorders, and cancer.
Read MoreMONTRÉAL, Feb. 4, 2021 /CNW Telbec/ - As part of its strategy to support Québec's life sciences sector through well-performing specialized funds, the Fonds de solidarité FTQ ("Fonds") is investing US$17.7 million (C$22.5 million) in Lumira IV. Over the years, Lumira has invested in Québec companies such as enGene, Kisoji, Opsens and IMV.
Read More